| 151 |
20705357 | First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. | 2011 Apr |
2 |
| 152 |
20864569 | Empowering induction therapy for locally advanced head and neck cancer. | 2011 Apr |
1 |
| 153 |
21252285 | Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. | 2011 Mar |
1 |
| 154 |
21258258 | Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? | 2011 Mar |
2 |
| 155 |
21266349 | EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. | 2011 Feb 1 |
3 |
| 156 |
21329967 | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. | 2011 May 1 |
1 |
| 157 |
21431282 | LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. | 2011 Jun |
4 |
| 158 |
21440325 | Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. | 2011 Jul |
1 |
| 159 |
21478906 | β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. | 2011 Sep 29 |
1 |
| 160 |
21681119 | Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. | 2011 Oct |
1 |
| 161 |
21782507 | Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. | 2011 Aug |
1 |
| 162 |
21809030 | A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency. | 2011 Oct |
1 |
| 163 |
22173497 | EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. | 2011 Dec |
3 |
| 164 |
22715590 | The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells. | 2011 |
4 |
| 165 |
19375813 | Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. | 2010 Jan |
6 |
| 166 |
20022809 | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. | 2010 Feb |
1 |
| 167 |
20215522 | Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. | 2010 Apr 1 |
15 |
| 168 |
20693797 | Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. | 2010 |
3 |
| 169 |
20726858 | Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. | 2010 Nov |
1 |
| 170 |
20959404 | cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. | 2010 Nov 1 |
5 |
| 171 |
19149612 | Targeted therapies in lung cancer. | 2009 |
1 |
| 172 |
19220256 | Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. | 2009 Jun |
1 |
| 173 |
19254954 | Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. | 2009 Jun 19 |
1 |
| 174 |
19259093 | Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. | 2009 Mar 10 |
1 |
| 175 |
19399750 | Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. | 2009 Oct |
2 |
| 176 |
19414362 | Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. | 2009 Apr |
2 |
| 177 |
19632939 | The role of cetuximab in the management of non-small-cell lung cancer. | 2009 Jul |
1 |
| 178 |
19724896 | Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. | 2009 Oct |
1 |
| 179 |
19785057 | Clinical relevance of monoclonal antibodies in non small cell lung cancer. | 2009 Sep |
1 |
| 180 |
19917871 | American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. | 2009 Dec 20 |
1 |
| 181 |
19956435 | Nuclear EGFR is required for cisplatin resistance and DNA repair. | 2009 Mar 8 |
7 |
| 182 |
17942395 | Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. | 2008 Jan 11 |
4 |
| 183 |
18196976 | NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. | 2008 Jan 1 |
1 |
| 184 |
18211286 | Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. | 2008 Feb |
1 |
| 185 |
18347929 | EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. | 2008 Mar |
7 |
| 186 |
18927293 | Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. | 2008 Oct 15 |
9 |
| 187 |
18980981 | Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. | 2008 Nov 1 |
2 |
| 188 |
19027738 | The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. | 2008 Dec 24 |
8 |
| 189 |
19047094 | Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. | 2008 Dec 1 |
1 |
| 190 |
17487368 | Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. | 2007 Jun |
2 |
| 191 |
17686445 | How could pharmacogenomics help improve patient survival? | 2007 Aug |
1 |
| 192 |
17876336 | Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? | 2007 Oct 8 |
3 |
| 193 |
18337622 | Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. | 2007 |
4 |
| 194 |
16442503 | Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. | 2006 Apr 14 |
1 |
| 195 |
16505093 | Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. | 2006 Feb |
1 |
| 196 |
16731747 | Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. | 2006 May |
1 |
| 197 |
16785992 | Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. | 2006 Nov 30 |
4 |
| 198 |
16932740 | p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. | 2006 Sep 20 |
2 |
| 199 |
16984384 | Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. | 2006 Oct |
3 |
| 200 |
17062690 | Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. | 2006 Oct 15 |
1 |